Safety and Efficacy of ARQ-154 Foam in Adolescent and Adult Subjects With Scalp and Body Psoriasis

A Phase 2b, 8-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-154 Foam 0.3% Administered QD in Adolescents and Adults With Scalp and Body Psoriasis

This study will assess the safety and efficacy of ARQ-154 foam vs placebo applied once a day for 56 days by subjects with scalp and body psoriasis

Study Overview

• Status: Completed
• Conditions: Plaque Psoriasis
• Intervention / Treatment: Drug: Roflumilast foam 0.3%; Drug: Vehicle foam

Detailed Description

This is a parallel group, double blind, vehicle-controlled study in which ARQ-154 foam or vehicle is applied once daily x 8 weeks to adolescent and adult subjects with scalp and body psoriasis

• Study Type: Interventional
• Enrollment (Actual): 304
• Phase: Phase 2

Contacts and Locations

Study Locations

• Australia
  • New South Wales
    • Kogarah, New South Wales, Australia, 2217
      • Arcutis Biotherapeutics Clinical Site 51
    • Westmead, New South Wales, Australia, 2145
      • Arcutis Biotherapeutics Clinical Site 52
  • South Australia
    • Hectorville, South Australia, Australia, 5073
      • Arcutis Biotherapeutics Clinical Site 54
  • Victoria
    • East Melbourne, Victoria, Australia, 3002
      • Arcutis Biotherapeutics Clinical Site 50
• Bulgaria
  • Pleven, Bulgaria, 5800
    • Arcutis Biotherapeutics Clinical Site 11
  • Sevlievo, Bulgaria, 5402
    • Arcutis Biotherapeutics Clinical Site 13
  • Sofia, Bulgaria, 1592
    • Arcutis Biotherapeutics Clinical Site 14
  • Sofia, Bulgaria, 1606
    • Arcutis Biotherapeutics Clinical Site 10
  • Stara Zagora, Bulgaria, 6003
    • Arcutis Biotherapeutics Clinical Site 12
• Canada
  • Alberta
    • Calgary, Alberta, Canada, T1Y0B4
      • Arcutis Biotherapeutics Clinical Site 64
  • Ontario
    • Barrie, Ontario, Canada, L4M 7G1
      • Arcutis Biotherapeutics Clinical Site 61
    • London, Ontario, Canada, N6H5L5
      • Arcutis Biotherapeutics Clinical Site 60
    • Peterborough, Ontario, Canada, K9J 5K2
      • Arcutis Biotherapeutics Clinical Site 62
    • Waterloo, Ontario, Canada, N2J 1C4
      • Arcutis Biotherapeutics Clinical Site 63
  • Quebec
    • Montréal, Quebec, Canada, H2X 2V1
      • Arcutis Biotherapeutics Clinical Site 66
    • Westmount, Quebec, Canada, H3Z 2S6
      • Arcutis Biotherapeutics Clinical Site 65
• United States
  • Arkansas
    • Rogers, Arkansas, United States, 72758
      • Arcutis Biotherapeutics Clinical Site 71
  • California
    • Fremont, California, United States, 94538
      • Arcutis Biotherapeutics Clinical Site 72
    • San Diego, California, United States, 92123
      • Arcutis Biotherapeutics Clinical Site 85
  • Connecticut
    • Cromwell, Connecticut, United States, 06416
      • Arcutis Biotherapeutics Clinical Site 21
  • Florida
    • Boynton Beach, Florida, United States, 33437
      • Arcutis Biotherapeutics Clinical Site 91
    • Coral Gables, Florida, United States, 33134
      • Arcutis Biotherapeutics Clinical Site 20
    • Miami, Florida, United States, 33144
      • Arcutis Biotherapeutics Clinical Site 88
    • Miami, Florida, United States, 33714
      • Arcutis Biotherapeutics Clinical Site 90
    • Sweetwater, Florida, United States, 33172
      • Arcutis Biotherapeutics Clinical Site 83
  • Illinois
    • Rolling Meadows, Illinois, United States, 60008
      • Arcutis Biotherapeutics Clinical Site 99
  • Indiana
    • Indianapolis, Indiana, United States, 46250
      • Arcutis Biotherapeutics Clinical Site 78
    • Plainfield, Indiana, United States, 46168
      • Arcutis Biotherapeutics Clinical Site 95
  • Kentucky
    • Louisville, Kentucky, United States, 40217
      • Arcutis Biotherapeutics Clinical Site 77
  • Louisiana
    • Covington, Louisiana, United States, 70433
      • Arcutis Biotherapeutics Clinical Site 79
    • Metairie, Louisiana, United States, 70006
      • Arcutis Biotherapeutics Clinical Site 94
  • Minnesota
    • Fridley, Minnesota, United States, 55432
      • Arcutis Biotherapeutics Clinical Site 73
  • Missouri
    • Saint Joseph, Missouri, United States, 64506
      • Arcutis Biotherapeutics Clinical Site 84
  • New Hampshire
    • Portsmouth, New Hampshire, United States, 03801
      • Arcutis Biotherapeutics Clinical Site 98
  • North Carolina
    • High Point, North Carolina, United States, 27262
      • Arcutis Biotherapeutics Clinical Site 87
  • Ohio
    • Bexley, Ohio, United States, 43209
      • Arcutis Biotherapeutics Clinical Site 96
  • Oregon
    • Portland, Oregon, United States, 97210
      • Arcutis Biotherapeutics Clinical Site 82
  • Pennsylvania
    • Broomall, Pennsylvania, United States, 19008
      • Arcutis Biotherapeutics Clinical Site 80
  • Tennessee
    • Murfreesboro, Tennessee, United States, 37130
      • Arcutis Biotherapeutics Clinical Site 97
  • Texas
    • Arlington, Texas, United States, 76011
      • Arcutis Biotherapeutics Site 70
    • Austin, Texas, United States, 78759
      • Arcutis Biotherapeutics Clinical Site 76
    • College Station, Texas, United States, 77845
      • Arcutis Biotherapeutics Clinical Site 86
    • Houston, Texas, United States, 77056
      • Arcutis Biotherapeutics Clinical Site 74
    • Pflugerville, Texas, United States, 78660
      • Arcutis Biotherapeutics Clinical Site 89
    • San Antonio, Texas, United States, 78213
      • Arcutis Biotherapeutics Clinical Site 93
  • Virginia
    • Norfolk, Virginia, United States, 23502
      • Arcutis Biotherapeutics Clinical Site 81
    • Richmond, Virginia, United States, 23220
      • Arcutis Biotherapeutics Clinical Site 75

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 12 years and older (ADULT, OLDER_ADULT, CHILD)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Participants legally competent to read, write, sign and give informed consent, or, in the case of adolscents, assent with consent of a parent(s) or legal guardian, as required by local laws.
• Males and females ages 12 years and older (inclusive) at the time of consent for assent (for adolescents).
• Scalp psoriasis with an Investigator Global Assessment of Scalp disease severity (S-IGA) of at least Mild ('2') at Baseline.
• A Psoriasis Scalp Severity Index (PSSI) score of at least 6 at Baseline.
• A PASI score of at least 2 (excluding the palms and soles) at Baseline.
• Clinical diagnosis of psoriasis vulgaris of at least 6 months duration as determined by the Investigator. Stable disease for the past 4 weeks.
• Females of childbearing potential (FOCBP) must have a negative serum pregnancy test at Screening (Visit 1) and a negative urine pregnancy test at Baseline (Visit 2).
• Females of non-childbearing potential must either be post-menopausal with spontaneous amenorrhea for at least 12 months or have undergone surgical sterilization.
• Subjects in good health as judged by the Investigator, based on medical history, physical examination, vital signs, serum chemistry labs, hematology values, and urinalysis.
• Subjects are considered reliable and capable of adhering to the Protocol and visit schedule according to the Investigator judgment.

Exclusion Criteria:

• Subjects who cannot discontinue medications and treatments prior to the Baseline visit and during the study according to Excluded Medications and Treatments.
• Planned excessive exposure of treated area(s) to either natural or artificial sunlight, tanning bed or other LED.
• Subjects currently taking lithium or antimalarial drugs.
• Planned initiation or changes to concomitant medication that could, in the opinion of the Investigator, affect psoriasis vulgaris (e.g. beta blockers, ACE inhibitors).
• Current diagnosis of non-plaque forms of psoriasis (e.g., guttate, erythrodermic/exfoliative, palmoplantar only involvement, or pustular psoriasis). Current diagnosis of drug-induced psoriasis.
• Subjects with any condition on the treatment area which, in the opinion of the Investigator, could confound efficacy measurements.
• Known allergies to excipients in ARQ-154.
• Subjects who cannot discontinue the use of strong P-450 cytochrome inhibitors e.g., indinavir, nelfinavir, ritonavir, clarithromycin, itraconazole, ketoconazole, nefazodone, saquinavir, suboxone and telithromycin for two weeks prior to the Baseline visit (Visit 2) and during the study.
• Subjects who cannot discontinue the use of strong P-450 cytochrome inducers e.g., efavirenz, nevirapine, glucocorticoids, barbiturates (including phenobarbital), phenytoin, rifampin, and carbamazepine for two weeks prior to the Baseline visit (Visit 2) and during the study.
• Subjects with PHQ-8 >/= 10 or modified PHQ-A >/= 10 at Screening or Baseline.
• Females who are pregnant, wishing to become pregnant during the study, or are breast-feeding.
• Subjects with any serious medical condition or laboratory abnormality that would prevent study participation or place the subject at significant risk, as determined by the Investigator.
• Subjects with a history of chronic alcohol or drug abuse within 6 months of initiation of the investigational product.
• Subjects with a history of a major surgery within 4 weeks prior to Baseline (Visit 2) or has a major surgery planned during the study.
• Subjects who are unable to communicate, read or understand the local language, or who display another condition, which in the Investigator's opinion, makes them unsuitable for clinical study participation.
• Current or a history of cancer within 5 years with the exception of fully treated skin basal cell carcinoma, cutaneous squamous cell carcinoma or carcinoma in situ of the cervix.
• Subjects with active infection that required oral or intravenous administration of antibiotics, antifungal, or antiviral agents within 7 days of Baseline/Day 0.
• Subjects who are family members of the clinical study site, clinical study staff, or sponsor, or family members residing in the same household of enrolled subjects.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: RANDOMIZED
• Interventional Model: PARALLEL
• Masking: QUADRUPLE

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: ARQ-154 foam 0.3%; active	Drug: Roflumilast foam 0.3%; experimental; Other Names: ARQ-154
PLACEBO_COMPARATOR: ARQ foam VehicleRQ-154 foam Vehicle; placebo	Drug: Vehicle foam; experimental; Other Names: placebo

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of Participants Achieving Success in the Scalp Investigator Global Assessment (S-IGA) Scale	The number of participants achieving success in the S-IGA scale is presented for each arm. Success is defined as an S-IGA score of 0 ('clear') or 1 ('almost clear'), plus a 2-grade improvement from baseline.The S-IGA is 5-point scale assessing the severity of plaque psoriasis on the scalp, with scores ranging from 0 ('clear') to 4 ('severe'). Higher scores indicate greater symptom severity.	Week 8

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of Participants Achieving Body Investigator Global Assessment (B-IGA) Success at Week 8	The number of participants achieving success in the B-IGA scale is presented for each arm. Success is defined as a B-IGA score of 0 ('clear') or 1 ('almost clear'), plus a 2-grade improvement from baseline. The B-IGA is 5-point scale assessing the severity of plaque psoriasis on the body, with scores ranging from 0 ('clear') to 4 ('severe'). Higher scores indicate greater symptom severity.	Week 8
Number of Participants Achieving Success in Scalp Itch Numerical Rating Scale (SI-NRS) Score	The number of participants with a baseline SI-NRS score ≥4 who achieve success (a ≥4-point improvement from Baseline) at Weeks 2, 4, and 8 is presented for each arm. The SI-NRS is a participant-reported rating of severity of itch at its highest intensity during the previous 24-hour period. The scale ranges from 0 ('no itch') to 10 ('worst imaginable itch'), with higher scores indicating greater symptom severity. Results are based on observed data only.	Baseline and Weeks 2, 4, 8
Change From Baseline in Psoriasis Symptoms Diary (PSD) Score	The change from baseline in total PSD scores at Weeks 4 and 8 is presented for each arm. The PSD is a 16-item questionnaire asking subjects to rate the severity of psoriasis-related symptoms in the past 24 hours. Each question is scored from 0 ("no symptoms") to 10 ("worst imaginable symptoms"). Scores range from 0 to 160, with higher scores indicating greater symptom severity.	Baseline and Weeks 4 and 8
Time to Achieve a 50% Reduction From Baseline in Psoriasis Scalp Severity Index (PSSI-50) Score	The time to achieve PSSI-50 (i.e., a 50% reduction from baseline in PSSI score) is presented for each arm. The PSSI measures the extent of psoriasis involvement and the severity of erythema, induration, and desquamation of the scalp. Involvement and severity of psoriasis for the PSSI is scored using a scale of 0 to 72, where 0 = no psoriasis and higher scores indicating greater symptom severity. Results are based on observed data only.	Up to 8 weeks
Number of Participants Achieving Psoriasis Scalp Severity Index-75 (PSSI-75)	The number of participants achieving a 75% reduction in PSSI score (i.e., PSSI-75) from baseline. The PSSI measures the extent of psoriasis involvement and the severity of erythema, induration, and desquamation of the scalp. Involvement and severity of psoriasis for the PSSI is scored using a scale of 0 to 72, where 0 = no psoriasis and higher scores indicate greater symptom severity. Results are based on observed data only.	Week 8
Number of Participants Achieving PSSI-90	The number of participants achieving a 90% reduction from baseline PSSI score (i.e., PSSI-90) is presented for each arm. The PSSI measures the extent of psoriasis involvement and the severity of erythema, induration, and desquamation of the scalp. Involvement and severity of psoriasis for the PSSI is scored using a scale of 0 to 72, where 0 = no psoriasis and higher scores indicate greater symptom severity. Results are based on observed data only.	Baseline and Week 8

Collaborators and Investigators

• Sponsor: Arcutis Biotherapeutics, Inc.

Study record dates

Study Major Dates

• Study Start (ACTUAL): January 13, 2020
• Primary Completion (ACTUAL): September 23, 2020
• Study Completion (ACTUAL): September 25, 2020

Study Registration Dates

• First Submitted: October 14, 2019
• First Submitted That Met QC Criteria: October 14, 2019
• First Posted (ACTUAL): October 16, 2019

Study Record Updates

• Last Update Posted (ACTUAL): October 26, 2022
• Last Update Submitted That Met QC Criteria: October 24, 2022
• Last Verified: October 1, 2022

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Skin Diseases; Skin Diseases, Papulosquamous; Psoriasis
• Other Study ID Numbers: ARQ-154-204

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No